News and Trends 10 Nov 2022 Avstera receives funding for cancer programs Avstera Therapeutics Corp. has announced the completion of its seed round to advance its lead cancer programs geared toward targeting solid tumors. The company intends to use the $4.55 million proceeds to enable its lead highly specific HDAC6i for IND filing targeting locally advanced and metastatic solid tumors by the end of next year. “Tumor […] November 10, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Researchers develop new nanoparticle to deliver drugs direct to macrophages How can a drug be delivered exactly where it is needed, while limiting the risk of side effects? The use of nanoparticles to encapsulate a drug to protect it and the body until it reaches its point of action is being increasingly studied. However, this requires identifying the right nanoparticle for each drug according to […] November 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 10 Nov 2022 Novo Nordisk supports Plant2Food platform with €27M funding Novo Nordisk Foundation will support new open collaborative platform, Plant2Food, to accelerate the development of plant-based foods with up to €27 million ($26.9m) over the next five years. The platform, Plant2Food, will include researchers and companies collaborating and exploring complex challenges within plant and food science and sharing new knowledge across sectors – without taking […] November 10, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Ascentage Pharma gets Chinese approval for solid tumor study Ascentage Pharma says its novel inhibitor of the embryonic ectoderm development (EED) protein, APG-5918, has been approved by the Center for Drug Evaluations (CDE) of China National Medical Products Administration (NMPA) to enter a phase I study in patients with advanced solid tumors or hematologic malignancies. Following the recent clearance for the study in the […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Novel branched lipid boosts mRNA delivery to cells A novel branched lipid that is highly stable in storage and is highly efficient in delivering mRNA to cells has been developed. Messenger RNA (mRNA) is a biological molecule that transfers the information coded by genes in the nucleus to the cytoplasm for protein synthesis by ribosomes. mRNA sequences can be designed to encode specific […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Minoryx and Neuraxpharm announce license agreement to further X-ALD treatment Minoryx Therapeutics and Neuraxpharm Group have announced the completion of a strategic license agreement. Minoryx is a biotech company that focuses on the development of treatments for orphan central nervous system (CNS) disorders while the Neuraxpharm Group is a pharmaceutical company focused on CNS therapies. Under the agreement, Minoryx grants Neuraxpharm exclusive European rights to […] November 10, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Looking for cancer clues? Copper may open new drug treatment doors For cancer cells to grow and spread around the human body, they need proteins that bind copper ions. New research about how cancer-related proteins bind the metal and how they interact with other proteins may open up potential new drug targets in the fight against cancer. Human cells need small amounts of the metal copper […] November 10, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 New radiopharmaceutical shrinks prostate cancer tumors Researchers in Japan and Germany say a radiopharmaceutical treatment targeting a prostate-specific membrane antigen effectively shrinks prostate tumors in mice. The team reported the anti-cancer treatment zeroes in on tumor cells with ‘laser precision.’ Recent developments, such as targeted α-therapies as a type of theranostics, are trying to tackle cancer. Theranostics is a one-two punch […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Funding for NRG Therapeutics to work on mitochondria link to Parkinson’s and ALS NRG Therapeutics, Ltd. has closed a £16 million ($18.2 million) series A financing. The funding was led by Omega Funds and joined by additional new investor Brandon Capital and founding investor Parkinson’s Virtual Biotech. NRG Therapeutics is using mitochondrial biology to develop disease-modifying therapeutics to slow or halt the progression of neurodegenerative disorders such as […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Best in Biotech 10 Nov 2022 The five hottest biotech startup companies in Brazil Brazil’s developing economy is supporting an emerging biotech startup scene. Catch a glimpse of the biotech companies causing a stir in Brazil. Over the decades, Brazil has grown into an agricultural powerhouse and has the biggest economy in South America. The nation is the world’s second-largest producer of biotech crops, with increasing land devoted to […] November 10, 2022 - 4 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2022 PrecisionLife supports Sosei Heptares to treat chronic diseases in more personalized way PrecisionLife, developers of precision medicine for chronic diseases, will be supporting biopharmaceutical group, Sosei Heptares, to develop better, more personalized treatment options. Specifically, global techbio PrecisionLife, will assess the precision medicine potential of a neuroscience target nominated by Sosei Heptares, that specializes in structure-based drug design targeting G protein-coupled receptors (GPCRs). Sosei Heptares will leverage […] November 9, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
More News! 9 Nov 2022 Better Juice launches naturally converting fruit juice sugars to prebiotics A new site housing technology to naturally turn the composition of fruit juice sugars including sucrose, glucose and fructose into better-for-you prebiotics has been opened by Better Juice Ltd. The Israeli sugar-reduction startup launched its first full-capacity manufacturing plant for full commercial production of sugar-reducing immobilized enzymes. The new facility, the company says, will allow […] November 9, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email